Gastric Cancer, Gastroesophageal-junction Cancer
Conditions
Brief summary
This is a multi-cohort, multi-center Phase II clinical study exploring the efficacy of treatment with either Adebrelimab plus SHR-A1811/SHR-A1904 and chemotherapy, or Adebrelimab plus SHR-8068 in patients with gastric or gastroesophageal junction (GEJ) cancer. The study also evaluates the safety and tolerability of these combination regimens.
Interventions
Adebrelimab injection.
SHR-A1811 for injection.
SHR-A1904 for injection.
SHR-8068 injection.
Sponsors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with histologically confirmed gastric or gastroesophageal junction adenocarcinoma who have not received prior anti-tumor therapy for gastric/gastroesophageal junction cancer. 2. Age: ≥18 and ≤70 years, both male and female. 3. Ability to provide fresh tumor tissue (preferred) or archival formalin-fixed paraffin-embedded (FFPE) tumor blocks/unstained slides obtained within 6 months before enrollment. 4. Availability of biomarker testing results before enrollment. 5. ECOG performance status of 0-1. 6. Life expectancy ≥ 6 months. 7. Adequate organ and bone marrow function. 8. Female participants must be either non-childbearing potential or of childbearing potential with a negative serum pregnancy test within 3 days prior to treatment initiation and not lactating. Childbearing-potential participants and their partners must agree to avoid sperm/ovum donation and comply with contraception requirements from informed consent signing until 8 months after the last dose. 9. Voluntarily signed informed consent form, with willingness and ability to comply with scheduled visits, treatments, laboratory tests, and study procedures.
Exclusion criteria
1. Known squamous cell carcinoma, undifferentiated carcinoma, mixed adenocarcinoma with other histologic types, or other non-adenocarcinoma gastric cancers. 2. 20% body weight loss within 2 months before enrollment. 3. Prior treatments: Anti-tumor therapy for gastric/gastroesophageal junction cancer; Participation in other drug trials with last dose ≤4 weeks or ≤5 half-lives (whichever longer) before enrollment; Major surgery within 28 days before enrollment; Live attenuated vaccination within 28 days before enrollment or planned during/within 60 days after treatment. 4. Known hypersensitivity to any study drug component (Adebrelimab, SHR-A1811, SHR-A1904, SHR-8068, fluorouracil, capecitabine, tegafur/gimeracil/oteracil) or humanized monoclonal antibodies. 5. Other malignancies within 5 years, except curatively treated basal/squamous cell skin cancer, superficial bladder cancer, cervical carcinoma in situ, ductal breast carcinoma in situ, or papillary thyroid cancer. 6. History of immunodeficiency, organ transplantation, or active autoimmune disease. 7. Clinically significant bleeding within 3 months or bleeding predisposition at screening; Arterial/venous thromboembolism within 6 months or at screening. 8. Non-healing wounds, active ulcers, or untreated fractures. 9. Active severe gastrointestinal disorders. 10. Interstitial pneumonia or lung disease. 11. Severe cardiovascular/cerebrovascular diseases or metabolic disorders. 12. Active HBV/HCV infection or HBV-HCV co-infection. 13. Active tuberculosis (TB) within 1 year by history/CT, or prior untreated active TB \>1 year ago. 14. Severe infection within 4 weeks before first dose; CTCAE ≥Grade 2 active infection requiring systemic antibiotics within 2 weeks; Chronic infections potentially affecting treatment/surgery. 15. History of drug abuse or illicit substance use. 16. Other conditions that may increase study risk, confound results, or render the patient unsuitable per investigator judgment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological complete response (pCR) rate assessed by the Pathology Review Committee (PRC). | Approximately 13 weeks. |
Secondary
| Measure | Time frame |
|---|---|
| Incidence and severity of serious adverse events (SAEs) evaluated per NCI-CTCAE v5.0. | Approximately 1 year. |
| Major pathological response (MPR) rate assessed by the Pathology Review Committee (PRC). | Approximately 13 weeks. |
| Pathological complete response (pCR) rate evaluated by the investigational site's pathology assessment. | Approximately 13 weeks. |
| Incidence and severity of adverse events (AEs) evaluated per NCI-CTCAE v5.0. | Approximately 1 year. |
| Disease-Free Survival (DFS). | Approximately 1 year. |
| Objective Response Rate (ORR). | Approximately 1 year. |
| Overall Survival (OS). | Approximately 2 years. |
| Event-Free Survival (EFS). | Approximately 1 year. |
Countries
China
Contacts
Primary ContactBin Bai
Outcome results
None listed